Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehab614 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epicardial Substrate Ablation in Symptomatic Brugada Syndrome Patients: An Updated Systematic Review and Single-arm Meta-analysis.
Heart Rhythm
January 2025
Dante Pazzanese Institute of Cardiology, Department of Electrophysiology, São Paulo, Brazil.
Background: Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist. In this setting, epicardial substrate ablation has emerged as a promising alternative for symptomatic patients.
View Article and Find Full Text PDFAdvances and Challenges in the Management of Brugada Syndrome: A Comprehensive Review.
Cureus
June 2024
Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA.
Article Synopsis
- Brugada syndrome (BrS) is an inherited heart condition that leads to abnormal heart rhythms and an increased risk of sudden cardiac death, primarily caused by mutations in the SCN5A gene.
- Diagnosis can be tricky due to its hidden ECG signs and symptoms that resemble other heart disorders, mostly affecting young, healthy males.
- Treatment mainly involves managing symptoms and preventing sudden death, primarily through implantable cardioverter-defibrillators (ICDs), with recent advancements in catheter ablation and specific medications like quinidine showing promise despite challenges in long-term management and availability.
Brugada syndrome: identification of subjects at risk and therapy.
Eur Heart J Suppl
April 2024
Division of Cardiology, Policlinico Casilino, Rome.
Brugada syndrome mainly affects young subjects with structurally normal heart and can cause x syncope or sudden death due to ventricular arrhythmias, even as the first manifestation, in approximately 5-10% of cases. To date, two questions remain open: how to recognize subjects who will experience arrhythmic events and how to treat them. The guidelines suggest treating subjects with a previous history of cardiac arrest or arrhythmogenic syncope, while they are unconclusive about the management of asymptomatic patients, who represent ∼90% of Brugada patients.
View Article and Find Full Text PDFCatheter Ablation for Channelopathies: When Is Less More?
J Clin Med
April 2024
Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ventricular fibrillation (VF) is a common cause of sudden cardiac death in patients with channelopathies, particularly in the young population. Although pharmacological treatment, cardiac sympathectomy, and implantable cardioverter defibrillators (ICD) have been the mainstay in the management of VF in patients with channelopathies, they are associated with significant adverse effects and complications, leading to poor quality of life. Given these drawbacks, catheter ablation has been proposed as a therapeutic option for patients with channelopathies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!